PEPTIDE GUARDIANResearch literacy for peptides

Guides

Immune: what the research shows

Compounds studied for immune signalling and inflammation. This guide covers 2 of them. For each one: what is established in people, the key studies, and its status.

From our publisherAMINOSWORK, the research peptide supplier behind Peptide Guardian, posts its third-party lab reports by lot number. Open the lab report library

KPV

Animal and cell studies only

KPV is a chain of three amino acids taken from the end of a natural hormone; it has calmed inflammation in cell and mouse studies, but it has never been tested in a human trial and is not an approved medicine.

Nothing is established in people. No human trial of KPV has been published, and a search of ClinicalTrials.gov on 18 November 2026 found no registered trial of it. The FDA reached the same result in 2026: no clinical studies, no case reports and no human exposure data by any route. Two related molecules did reach early human testing, but they are not KPV and their results cannot be transferred to it. One is K(D)PT, a different three-amino-acid peptide, which was reported as well tolerated in a randomised phase 2a trial in ulcerative colitis in 2017. The other is CZEN-002, a larger peptide built from the KPV sequence, which a company announcement in 2004 said had been tried as a vaginal gel in 20 women with a yeast infection; no journal report of that study was found.

Key studies

  • Review, 2026. The FDA found no clinical study and no human exposure data for KPV by any route, and concluded that 'potential safety risks associated with the use of KPV in humans are unknown'. Source: fda.gov
  • Review, 2008. The authors described alpha-MSH as acting through melanocortin receptors to damp inflammation in animal models of fever, skin inflammation, arthritis and inflammation of several organs. Source: pubmed.ncbi.nlm.nih.gov
  • Animal study, 2026. The packaged form survived the gut better and reached the inflamed colon 3.8 times more than plain KPV, and worked better than plain KPV even when much less was given. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not approved. Not on the pharmacy compounding list. Named in a draft federal policy of 30 October 2026.
In sport
Not named; no approval found anywhere, so S0 applies: prohibited at all times.

All 15 studies on the KPV page

Thymosin alpha-1

Late-stage human trials

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid immune peptide that is licensed as a medicine in some countries but not in the United States; it has been tested in many human trials, and the largest and best-designed ones did not show a clear benefit.

Thymosin alpha-1 has been tested in thousands of patients, which sets it apart from most research peptides. What is established is that it was generally well tolerated in trials and can shift some blood markers of immune function. What is not established is that it improves outcomes that matter to patients. The largest trial (1,106 adults with sepsis) found no reduction in deaths, and a 2025 pooled analysis of 11 sepsis trials found fewer deaths overall but no significant benefit when only the high-quality trials were counted. The only double-blind placebo-controlled hepatitis B trial was negative, and a 2026 Cochrane review of 10 hepatitis B trials found it may reduce deaths but rated that evidence very low certainty, its authors saying they are not sure it has any effect. A 552-patient hepatitis C trial found no overall difference in cure rates, and the COVID-19 evidence is mixed and mostly not randomised. No trial was found that tested it in healthy people for general immune support.

Key studies

  • Human trial, 2026. Adding thymosin alpha-1 significantly increased survival without a liver transplant at 90 days, according to the abstract, which does not give the percentages. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2025. Death from any cause within 28 days occurred in 127 patients (23.4%) on thymosin alpha-1 and 132 (24.1%) on placebo, with no significant difference. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2023. Recovery was not significantly faster with thymalfasin, in patients on low-flow oxygen or on high-flow oxygen. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not FDA-approved. Not on the US pharmacy compounding list. Approved in some other countries, including Italy.
In sport
Not named on 2026 or 2027 Lists; approved in Italy, so outside S0.

All 14 studies on the Thymosin alpha-1 page

Before you trust any seller

A study tells you about the compound. It tells you nothing about what is in a particular vial. How to read a lab report

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sign up and it opens right away.